The list includes influenza virus antigen (haemagglutinin and neuraminidase antigens) , Bordetella pertussis antigen (pertussis toxin, filamentous haemagglutinin and pertactin) , human papilloma virus (HPV) antigen (glycoprotein) , Helicobacterpylori antigen (capsula polysaccharides of serogrup A, B, C, Y and W-1,5) , tetanus toxoid, diphtheria antigen (diphtheria toxoid) , pneumococcal antigen (Streptococcus pnemoniae type 3 capsular polysaccharide) , tuberculosis antigen, human immunodeficiency virus (HIV) antigen (GP-1,0, GP-1,0, plδ, Tat, Gag, Pol and Env) , cholera antigen (cholera toxin B subunit) , staphylococcal antigen (staphylococcal enterotoxin B) , shigella antigen (shigella polysaccharides) , vesicular stomatitis virus antigen (vesicular stomatitis virus glycoprotein) , cytomegalovirus (CMV) antigen,
The immunotherapeutic and prophylactic vaccine according to claim 3, wherein the pathogenic bacteria derived antigen is selected from a group consisting of Bordetella pertussis antigen (pertussis toxin, filamentous hemagglutinin and pertactin) , tetanus toxoid, diphtheria antigen (diphtheria toxoid) , Helicobacter pylori antigen (capsula polysaccharides of serogrup A, B, C, Y and W-1,5) , pneumococcal antigen (Streptococcus pnemoniae type 3 capsular polysaccharide) , tuberculosis antigen, cholera antigen (cholera toxin B subunit) , staphylococcal antigen
The immunotherapeutic and prophylactic vaccine according to claim 3, wherein the pathogenic bacteria derived antigen is selected from a group consisting of Bordetella pertussis antigen (pertussis toxin, filamentous hemagglutinin and pertactin) , tetanus toxoid, diphtheria antigen (diphtheria toxoid) , Helicobacter pylori antigen (capsula polysaccharides of serogrup A, B, C, Y and W-1,5) , pneumococcal antigen (Streptococcus pnemoniae type 3 capsular polysaccharide) , tuberculosis antigen, cholera antigen (cholera toxin B subunit) , staphylococcal antigen
The list includes influenza virus antigen (haemagglutinin and neuraminidase antigens) , Bordetella pertussis antigen (pertussis toxin, filamentous haemagglutinin and pertactin) , human papilloma virus (HPV) antigen (glycoprotein) , Helicobacterpylori antigen (capsula polysaccharides of serogrup A, B, C, Y and W-1,5) , tetanus toxoid, diphtheria antigen (diphtheria toxoid) , pneumococcal antigen (Streptococcus pnemoniae type 3 capsular polysaccharide) , tuberculosis antigen, human immunodeficiency virus (HIV) antigen (GP-1,0, GP-1,0, plδ, Tat, Gag, Pol and Env) , cholera antigen (cholera toxin B subunit) , staphylococcal antigen (staphylococcal enterotoxin B) , shigella antigen (shigella polysaccharides) , vesicular stomatitis virus antigen (vesicular stomatitis virus glycoprotein) , cytomegalovirus (CMV) antigen,
... buffer solution emulsified in CFA without the peptides sequence. Each mouse treated with P2 was also treated with 2,0 ng pertussis toxin in 1,0 ?L PBS i.p. at the days 0 and 2 post-immunisation. Controls were injected i.p. with equal volumes of PBS and pertussis toxin free of the peptides sequence. Motor strength, posture and coordination were evaluated daily until the 60th day postinoculation besides eletroneur...
... tamponada de fosfato (PBS), emulsionada em AFC desprovida da sequência 58,81 de peptídeos P2, injetada no mesmo local, na mesma quantidade e forma. Cada camundongo tratado com P2 recebeu 2,0 ng de toxina pertussis em 1,0 ?L de PBS intraperitonealmente (i.p.) nos dias 0 e 2 pós-imunização (p.i.). No grupo controle, volumes iguais de PBS e toxina pertussis foram administrados pela mesma via sem o peptídeo. Avaliações da motricidade foram realizadas diariamente até o 60º dia, além de análises funciona...
...by the blockage of exocytosis and degranulation. The aim of this study was to evaluate the effect of this drug on the development of EAE. For this, MOG/CFA-immunized female C57BL/6 mice were treated with ketotifen fumarate. The effect of treatment was determined by body weight loss and clinical score. Subsequently, EAE-associated histopathological and immunological parameters, as well as breakdown of blood...
...e trabalho foi avaliar o efeito desta droga no desenvolvimento da EAE. Para isto, camundongos C57BL/6 fêmeas submetidas à indução da EAE através da imunização com MOG/CFA e injeção de toxina pertussis. foram tratados com fumarato de cetotifeno (0,4 mg/kg via intraperitoneal) durante 11 dias, a partir do 7º dia após a indução. O efeito do tratamento no desenvolvimento clínico da EAE foi determinado pela avaliação de peso corporal e escore clínico. Posteriormente, parâmetros histopatológ...
Inglês
Português
Resultados da busca para 
